ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS
Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells. Further disclosed is a method of treating multiple myeloma using an anti-NTB-A antibody drug conjugate, which optionally includes an anti-NTB-A antibody as disclosed herein.
1 . An isolated monoclonal antibody comprising VH and VL domains sharing at least 80% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2.
2 . The antibody of claim 1 , wherein the VH and VL domains share at least 90% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2.
3 . The antibody of claim 1 , wherein the VH and VL domains share at least 95% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2.
4 . The antibody of claim 1 , wherein the VH and VL domains share at least 99% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2.
5 . The antibody of claim 2 , wherein the antibody is chimeric or humanized.
6 . The antibody of claim 1 , wherein the antibody is conjugated to a cytotoxic or cytostatic agent.
7 . The antibody of claim 2 , wherein the antibody is conjugated to a cytotoxic or cytostatic agent.
8 . The antibody of claim 3 , wherein the antibody is conjugated to a cytotoxic or cytostatic agent.
9 . The antibody of claim 4 , wherein the antibody is conjugated to a cytotoxic or cytostatic agent.
10 . The antibody of claim 5 , wherein the antibody is conjugated to a cytotoxic or cytostatic agent.
11 . A pharmaceutical composition comprising:
the antibody of claim 1 ; and
a pharmaceutically compatible ingredient.
12 . A pharmaceutical composition comprising:
the antibody of claim 2 ; and
a pharmaceutically compatible ingredient.
13 . A pharmaceutical composition comprising:
the antibody of claim 3 ; and
a pharmaceutically compatible ingredient.
14 . A pharmaceutical composition comprising:
the antibody of claim 4 ; and
a pharmaceutically compatible ingredient.
15 . A pharmaceutical composition comprising:
the antibody of claim 5 ; and
a pharmaceutically compatible ingredient.
16 . An antibody drug conjugate comprising an antibody conjugated to a cytotoxic agent, wherein the antibody comprises VH and VL domains sharing at least 80% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2.
17 . An antibody drug conjugate comprising an antibody conjugated to a cytotoxic agent, wherein the antibody comprises VH and VL domains sharing at least 90% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2.
18 . A pharmaceutical composition comprising the antibody drug conjugate of claim 16 .
19 . A pharmaceutical composition comprising the antibody drug conjugate of claim 17 .